| Literature DB >> 31309419 |
Gi-June Min1, Silvia Park1, Sung-Soo Park1, Jae-Ho Yoon1, Sung-Eun Lee1, Byung-Sik Cho1,2, Ki-Seong Eom1,2, Seok Lee1,2, Hee-Je Kim1,2, Chang-Ki Min1,2, Seok-Goo Cho1, Dong-Wook Kim1,2, Jong-Wook Lee1, Yoo-Jin Kim3,4.
Abstract
Graft-versus-host disease (GVHD) is a serious complication of allogeneic stem cell transplantation (SCT). Here, we report a rare case of GVHD involving the central nervous system (CNS). A 35-year-old woman was diagnosed with myelodysplastic syndrome unclassifiable and underwent allogeneic peripheral blood SCT for disease progression to myelodysplastic syndrome with excess blasts-2. One year following SCT, she experienced chronic oral and hepatic GVHD symptoms, which were managed with oral steroids and tacrolimus. Sixteen months after SCT, she developed sudden-onset, generalized, tonic-clonic-type seizures. Magnetic resonance imaging and cerebrospinal fluid evaluation showed multiple discrete white lesions and elevated IgG levels. Brain biopsy revealed periventricular plaques with the destruction of axons, representing a demyelinating disease of the CNS. We diagnosed the case as CNS GVHD. Neurologic symptoms gradually improved with methylprednisolone pulse therapy and total plasma exchange combined with a calcineurin inhibitor; the brain lesions nearly disappeared after decreasing steroid maintenance dosage, and were completely resolved 1 year after the onset of CNS GVHD. The patient is CNS GVHD-symptom-free, 3-year post-transplantation. Thus, CNS GVHD should be considered in cases of newly developed neurologic symptoms in SCT recipients showing evidence of preceding chronic GVHD.Entities:
Keywords: Allogeneic stem cell transplantation; Central nervous system graft-versus-host disease; Demyelination
Mesh:
Substances:
Year: 2019 PMID: 31309419 DOI: 10.1007/s12185-019-02702-1
Source DB: PubMed Journal: Int J Hematol ISSN: 0925-5710 Impact factor: 2.490